Solid Biosciences Inc. (NASDAQ:SLDB)
| Market Cap | $697.57M+27.3% |
| Revenue (ttm) | $0 |
| Net Income | -$215.27M-28.8% |
| EPS | -$1.79+21.8% |
| Shares Out | 111.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,558,939 |
| Open | $6.22 |
| Previous Close | $6.44 |
| Day's Range | $6.19 - $6.53 |
| 52-Week Range | $4.65 - $11.45 |
| Beta | 2.63 |
| Analysts | Buy |
| Price Target | $22.25(+256.00%) |
| Earnings Date | Mar 18, 2027 |
About SLDB
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating SLDB in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 18, 2027Earnings report
$SLDB stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SLDB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SLDB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SLDB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SLDB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SLDB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SLDB
| VTIVanguard Morningstar Total Stock Market ETF | $15.15M |
| IWMiShares Russell 2000 ETF | $12.71M |
| XBIState Street SPDR S&P Biotech ETF | $11.55M |
| VXFVanguard Extended Market ETF | $4.59M |
| IBBiShares Biotechnology ETF | $4.30M |
| DFASDimensional - US Small Cap ETF | $3.95M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from SLDB’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| IBRN | iShares Neuroscience and Healthcare ETF | 0.91% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.79% |
| MNTL | Tema Neuroscience And Mental Health ETF | 0.57% |
| GNMX | Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | 0.50% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.49% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.38% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.31% |
| IWC | iShares Micro-Cap ETF | 0.14% |
| OPTZ | Optimize Strategy Index ETF | 0.13% |
| XBI | State Street SPDR S&P Biotech ETF | 0.12% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.07% |
| VMO.TO | Vanguard Global Momentum Factor ETF | 0.06% |
Weight is the stock’s share of each fund’s holdings.
